XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash flows from operating activities:    
Net loss $ (26,747,531) $ (16,745,260)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 827,327 451,386
Amortization of intangible assets 556,554 442,615
Change in value of common stock warrants 520,025 51,000
Stock-based compensation 5,251,166 3,773,134
Amortization of premiums on investments 139,659 154,655
Deferred rent (31,783) 241,708
Gain on investment in affiliated entity (6,775,450) (6,508,836)
Gain on sale of intangible assets (1,000,000) (1,000,000)
Changes in operating assets and liabilities:    
Accounts receivable (3,032,891) (2,804,638)
Prepaid expenses and other current assets (270,785) 246,675
Prepaid expenses and other current assets from affiliated entity (1,271,605) 337,005
Other assets (655,334) (106,774)
Accounts payable and accrued expenses (247,009) (505,047)
Accrued clinical trial expenses 2,405,804 539,055
Accounts payable and accrued expenses due to affiliated entity 435,922 3,388,610
Deferred revenue 1,323,827 (2,895,227)
Deferred revenue from affiliated entity (437,827) (150,000)
Net cash used in operating activities (29,009,931) (21,089,939)
Cash flows from investing activities:    
Purchases of investments (27,985,410) (35,193,487)
Maturities of investments 27,662,695 3,745,000
Purchases of capital assets (2,196,896) (1,173,024)
Proceeds from sale of intangible assets 1,000,000 1,000,000
Purchase of intangible assets and other assets (1,200,000) 0
Net cash used in investing activities (2,719,611) (31,621,511)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 1,301,435 81,902,363
Proceeds from stock option and warrant exercises, net of tax payments 1,395,346 562,679
Other financing activities (149,559) 0
Net cash provided by financing activities 2,547,222 82,465,042
Decrease in cash and cash equivalents (29,182,320) 29,753,592
Cash and cash equivalents, beginning of period 57,632,693 40,543,982
Cash and cash equivalents, end of period 28,450,373 70,297,574
Supplemental disclosure of non-cash activities    
Common stock issued for purchase of intangible assets and other assets 4,300,000 0
Change in amounts accrued for purchases of property and equipment (110,136) 190,109
Lease incentive recorded as fixed assets and deferred rent $ 134,500 $ 0